Who is sponsoring NCT05043532?

NCT05043532 is sponsored by Orlando Health, Inc..

What drugs are being tested in NCT05043532?

Interventions in NCT05043532: 2 passes during EUS-guided fine needle biopsy, 3 passes during EUS-guided fine needle biopsy.

What condition does NCT05043532 study?

NCT05043532 studies Pancreatic Cancer, Pancreatic Neoplasms, Adenocarcinoma of the Pancreas.

Is NCT05043532 still recruiting?

NCT05043532 is currently status unknown. Last updated 12 January 2023.

Last reviewed 2023-01-12 · How we verify

NCT05043532

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Randomized Trial for Optimal Number of Passes Required for Molecular Profiling During EUS-FNB of Pancreatic Cancer

Status unknown NA Last updated 12 January 2023

What this trial tests

NA trial testing 2 passes during EUS-guided fine needle biopsy in Pancreatic Cancer in 33 participants. Status unknown.

Timeline

18 August 2021

Primary endpoint
1 March 2023

30 June 2023

Quick facts

Lead sponsor	Orlando Health, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	diagnostic
Enrollment	33
Start date	18 August 2021
Primary completion	1 March 2023
Estimated completion	30 June 2023
Sites	1 location across United States

Drugs / interventions tested

2 passes during EUS-guided fine needle biopsy
3 passes during EUS-guided fine needle biopsy

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Pancreatic Neoplasms — all drugs for Pancreatic Neoplasms →
Adenocarcinoma of the Pancreas — all drugs for Adenocarcinoma of the Pancreas →

Sponsor

Orlando Health, Inc. — full company profile →

Who can join

18 and older, any sex, with Pancreatic Cancer or Pancreatic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized trial to evaluate the optimal number of passes required during endoscopic ultrasound-guided fine needle biopsy for molecular profiling in pancreatic cancer

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Standardisation of EUS-guided FNB technique for molecular profiling in pancreatic cancer: results of a randomised trial.
Bang JY, Jhala N, Seth A, Krall K, et al · · 2023 · cited 21× · PMID 37041069 · DOI 10.1136/gutjnl-2023-329495

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Orlando Health, Inc. trials

Trials by the same sponsor.

NCT07406698 — Strategic Timing of Endoscopic Interventions in Infected Necrotizing Pancreatitis · NA · recruiting
NCT06178315 — EUS-guided Celiac Plexus Block vs. Sham in Chronic Pancreatitis · NA · recruiting
NCT06576869 — Timing of Tourniquet Release · NA · completed
NCT04231279 — Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency · Phase 3 · terminated
NCT05043415 — Randomized Trial of Immediate Endoscopic Necrosectomy vs. Step-up Endoscopic Interventions in Necrotizing Pancreatitis · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05043532 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Orlando Health, Inc.
Last refreshed: 12 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05043532.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing